D. Bell

发表

Short- and long-term biological variation of cardiac troponin I in healthy individuals, and patients with end-stage renal failure requiring haemodialysis or cardiomyopathy

S. Vasikaran, J. Rankin, N. Lan, 2020, Clinical chemistry and laboratory medicine.

Revisiting the Biological Variability of Cardiac Troponin: Implications for Clinical Practice.

N. Lan, D. Bell, 2019, The Clinical biochemist. Reviews.

Plasma cholesterol in adults with phenylketonuria

C. Mamotte, J. Burnett, A. Hooper, 2015, Pathology.

The Need to Calculate Target Glucose Levels When Measuring Changes in Insulin Sensitivity During Interventions for Individuals With Type 2 Diabetes

J. Chase, N. A. Othman, P. Docherty, 2018, Journal of diabetes science and technology.

Improvements in Glucose Metabolism and Insulin Sensitivity with a Low-Carbohydrate Diet in Obese Patients with Type 2 Diabetes

J. Chase, K. Clarke, P. Docherty, 2013, Journal of the American College of Nutrition.

Studies in Insulin Resistance following Very Low Calorie Diet and/or Gastric Bypass Surgery

D. Macartney-Coxson, R. Stubbs, D. Bell, 2011, Obesity surgery.

Update on the diagnosis, treatment and management of rare genetic lipid disorders.

R. Hegele, J. Burnett, A. Hooper, 2019, Pathology.

The hypertriglyceridaemic waist in New Zealand Maori.

J. Mann, Sheila M. Williams, D. Bell, 2004, Asia Pacific journal of clinical nutrition.

Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome

G. Watts, B. Yeap, P. G. Fegan, 2019, Diabetic medicine : a journal of the British Diabetic Association.

Screening for familial hypercholesterolaemia

G. Watts, F. V. van Bockxmeer, J. Burnett, 2012, Pathology.

Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit.

G. Watts, B. Yeap, P. G. Fegan, 2020, Heart, lung & circulation.

Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis

G. Hillis, G. Watts, J. Burnett, 2018, Clinical cardiology.

Improving the detection of familial hypercholesterolaemia.

G. Watts, Andrew C Martin, T. Brett, 2019, Pathology.

Impact of the Australian gender specific thresholds using the Abbott high sensitivity troponin I assay in clinical care.

G. Hillis, S. Vasikaran, J. Rankin, 2017, Pathology.

Can patients be accurately assessed for familial hypercholesterolaemia in primary care?

Andrew B. Kirke, G. Watts, S. Burrows, 2014, Heart, lung & circulation.

Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner.

F. V. van Bockxmeer, J. Burnett, J. Pang, 2014, Atherosclerosis.

Genetic analysis of familial hypercholesterolaemia in Western Australia.

G. Watts, F. V. van Bockxmeer, J. Burnett, 2012, Atherosclerosis.

Systematic detection of familial hypercholesterolaemia in primary health care: a community based prospective study of three methods.

Andrew B. Kirke, J. Emery, G. Watts, 2015, Heart, lung & circulation.

Monogenic diabetes due to an INSR mutation in a child with severe insulin resistance

C. S. Choong, A. Hooper, D. Bell, 2021, Endocrinology, diabetes & metabolism case reports.

The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory.

G. Watts, F. V. van Bockxmeer, J. Burnett, 2015, Clinica chimica acta; international journal of clinical chemistry.

A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment

G. Watts, E. Moses, J. Burnett, 2019, Clinical genetics.

Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services.

Andrew B. Kirke, G. Watts, A. Vickery, 2014, Heart, lung & circulation.

Plasma poltergeists: a negative cortisol interference leading to a false diagnosis of adrenal insufficiency.

John G Lewis, C. Florkowski, D. Bell, 2012, Clinica chimica acta; international journal of clinical chemistry.

Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia.

G. Watts, J. Burnett, D. Chan, 2020, Clinica chimica acta; international journal of clinical chemistry.

Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?

G. Watts, D. Bell, M. M. Page, 2019, Clinical genetics.

25-Hydroxyvitamin D C3-epimer is universally present in neonatal Western Australian samples but is unlikely to contribute to diagnostic misclassification

P. Glendenning, S. Vasikaran, B. Cooke, 2016, Annals of clinical biochemistry.

Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines.

G. Watts, K. Burns, N. Lan, 2020, Current opinion in endocrinology, diabetes, and obesity.

A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia.

E. Moses, J. Burnett, D. Chan, 2022, Journal of clinical lipidology.

Parent–child genetic testing for familial hypercholesterolaemia in an Australian context

G. Watts, R. Norman, J. Burnett, 2018, Journal of paediatrics and child health.

Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies

G. Watts, Andrew C Martin, T. Brett, 2017, Current opinion in lipidology.

Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does it Make a Difference in the Clinic?

G. Watts, J. Burnett, D. Chan, 2019, Clinical chemistry.

Progress in the care of familial hypercholesterolaemia: 2016

G. Watts, D. Bell, G. Watts, 2016, The Medical journal of Australia.

Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.

G. Watts, J. Burnett, A. Hooper, 2014, Best practice & research. Clinical endocrinology & metabolism.

A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia

G. Watts, J. Burnett, D. Chan, 2018, The Journal of clinical endocrinology and metabolism.

Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry.

P. Clifton, G. Watts, K. Kostner, 2020, Heart, lung & circulation.

Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit.

G. Hillis, G. Watts, C. Schultz, 2015, Journal of clinical lipidology.

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

J. Burnett, A. Hooper, D. Bell, 2011, Expert opinion on investigational drugs.

Pilot study of universal screening of children and child‐parent cascade testing for familial hypercholesterolaemia in Australia

G. Watts, J. Burnett, R. Norman, 2021, Journal of paediatrics and child health.

Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia.

G. Watts, J. Burnett, A. Hooper, 2016, Pathology.

Challenges in the care of familial hypercholesterolemia: a community care perspective

G. Watts, A. Vickery, J. Pang, 2015, Expert review of cardiovascular therapy.

Familial hypercholesterolaemia: challenges in primary care

G. Watts, A. Vickery, J. Pang, 2015 .

The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia.

G. Watts, J. Burnett, D. Bell, 2020, Pathology.

Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons

G. Watts, M. Bulsara, C. Bulsara, 2017, BMJ Open.

Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).

E. Moses, J. Burnett, D. Chan, 2021, Atherosclerosis.

Attainment of Lipid Targets Following Coronary Artery Bypass Graft Surgery: Can We Do Better?

B. Yeap, P. G. Fegan, R. Larbalestier, 2022, Journal of lipid and atherosclerosis.

Screening for familial hypercholesterolemia: primary care applications

G. Watts, D. Bell, 2015 .

Response to Familial Hypercholesterolemia: An Under‐recognized but Significant Concern in Cardiology Practice Foody JM et al. Clin Cardiol. doi: 10.1002/clc.22223.

G. Watts, D. Bell, 2014, Clinical cardiology.

The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats

G. Watts, J. Burnett, A. Hooper, 2018, Current Atherosclerosis Reports.

Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia.

Andrew B. Kirke, G. Watts, A. Vickery, 2014, Heart, lung & circulation.

Investigating hypophosphataemia

P. Glendenning, R. Clifton-Bligh, D. Bell, 2014, BMJ : British Medical Journal.

RATIONAL TESTING Investigating hypophosphataemia

P. Glendenning, R. Clifton-Bligh, D. Bell, 2014 .

Opportunistic screening for familial hypercholesterolaemia via a community laboratory

G. Watts, F. V. van Bockxmeer, J. Burnett, 2012, Annals of clinical biochemistry.

An opportunity to improve secondary prevention with icosapent ethyl in patients who have undergone coronary artery bypass graft surgery.

G. Dwivedi, R. Larbalestier, N. Lan, 2021, Cardiovascular revascularization medicine : including molecular interventions.

Knowledge and Practices Regarding Familial Hypercholesterolaemia Among General Practitioners

Andrew B. Kirke, G. Watts, A. Vickery, 2013 .

Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia.

G. Watts, F. V. van Bockxmeer, J. Burnett, 2013, Clinica chimica acta; international journal of clinical chemistry.

Impact of Telephoning the Requestors of Individuals Found to be at High Risk of Familial Hypercholesterolaemia

G. Watts, J. Burnett, F. V. Bockxmeer, 2013 .

Design, development and deployment of a web-based patient registry for rare genetic lipid disorders.

G. Watts, M. Bellgard, J. Burnett, 2020, Pathology.

Contemporary and Novel Therapeutic Options for Hypertriglyceridemia.

G. Watts, D. Bell, 2015, Clinical therapeutics.

An audit of pharmacists’ knowledge of familial hypercholesterolaemia: Implications for community healthcare

G. Watts, I. Krass, D. Bell, 2013 .

Patients with type 1 diabetes in a tertiary setting do not attain recommended lipid targets.

G. Watts, B. Yeap, P. G. Fegan, 2020, Diabetes & metabolism.

Dyslipidaemia in adults with type 1 diabetes—when to treat?

G. Watts, B. Yeap, P. G. Fegan, 2018, Diabetes/metabolism research and reviews.

Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.

G. Watts, P. O'Leary, F. V. van Bockxmeer, 2015, Atherosclerosis.

Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia.

Andrew B. Kirke, A. Keech, H. White, 2020, Heart, lung & circulation.

Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians

G. Watts, K. Kostner, C. Chow, 2021, Internal medicine journal.

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

Andrew B. Kirke, Clara K. Chow, A. Keech, 2021, American journal of preventive cardiology.

Optimising strategies for the detection of familial hypercholesterolaemia

D. Bell, 2016 .

Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.

G. Watts, F. V. van Bockxmeer, J. Burnett, 2015, International journal of cardiology.

Long-Term Outcomes of a Cohort of Hypertensive Subjects in Rural Ecuador.

M. Roncaglioni, G. Tognoni, F. Avanzini, 2019, Global heart.

An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.

G. Watts, J. Burnett, C. Schultz, 2020, Atherosclerosis.

Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions.

G. Watts, J. Burnett, D. Chan, 2016, Journal of clinical lipidology.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

G. Watts, J. Burnett, A. Hooper, 2012, Vascular health and risk management.

Screening for lipid disorders

G. Watts, F. V. van Bockxmeer, J. Burnett, 2012, Pathology.

Clinical utility gene card for: Sitosterolaemia

R. Hegele, J. Burnett, A. Hooper, 2016, European Journal of Human Genetics.

A new approach to design and implement a lifestyle intervention programme to prevent type 2 diabetes in New Zealand Maori.

Roanne Hurley, J. Mann, Sheila M. Williams, 2003, Asia Pacific Journal of Clinical Nutrition.

A high pressure liquid chromatography method for separation of prolactin forms

S. Vasikaran, D. Bell, K. Hoad, 2012, Annals of clinical biochemistry.

The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes

C. Elley, J. Mann, J. I. Mann, 2012, Diabetologia.

Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes

G. Watts, P. G. Fegan, N. Lan, 2022, Current opinion in endocrinology, diabetes, and obesity.

High‐Sensitivity Cardiac Troponin I Improves Cardiovascular Risk Prediction in Older Men: HIMS (The Health in Men Study)

G. Hankey, S. Vasikaran, J. Golledge, 2019, Journal of the American Heart Association.

Implementation of a successful lifestyle intervention programme for New Zealand Maori to reduce the risk of type 2 diabetes and cardiovascular disease.

J. Mann, Sheila M. Williams, A. Goulding, 2003, Asia Pacific journal of clinical nutrition.

The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension

G. Hillis, G. Watts, C. Schultz, 2017, Current Hypertension Reports.

Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB) – Update 2014

R. Hegele, J. Burnett, A. Hooper, 2014, European Journal of Human Genetics.

Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB)

R. Hegele, J. Burnett, A. Hooper, 2012, European Journal of Human Genetics.

The adrenal vein sampling outcomes study (AVOS): success rates following adrenalectomy for unilateral primary aldosteronism.

P. Glendenning, S. Vasikaran, Jun Yang, 2023, Pathology.

CD1-2 Acute changes in insulin sensitivity with very low calorie diet (VLCD) and gastric bypass

R. Stubbs, D. Macartney, D. Bell, 2008 .